4 min. Read

Six years of Oura’s financials: Revenue, profits, marketing spend and more

Issue 370
Welcome back to E&O: a subscribers-only weekly-ish newsletter focused on the business, regulation, and effectiveness of health tech.

Oura Farming

• • •

E&O started more than seven years ago with a deep dive into Livongo -- a company that was just about to IPO. My first post was an attempt to estimate what might be in the company's eventual S-1 once it came to light...
This week I have six years of

It's a good one, too.

This article is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

ACCESS Model’s first dropout? Plus: A few new participants

5.08.26

6 min. Read

Are these Utah’s next four AI experiments? Plus: More on the Utah Pharmacy Board’s questions about Doctronic

4.17.26

9 min. Read

Emails show how Doctronic’s AI pilot blindsided Utah’s Medical Board

4.10.26

13 min. Read

Quiet funding rounds. Plus: Digital health-related clinical trial round-ups

3.20.26

5 min. Read

Details: Vida Health’s brief GLP-1 rollout in Mass. Plus: CMS says Freespira not DME

3.13.26

7 min. Read

ACCESS Model’s shockingly low payments. DMHT Rx count.

2.13.26

7 min. Read

HLTH acquisition price. Estimating Pomelo Care pricing, revenue, and more

1.09.26

7 min. Read

CMS to pay for ADHD DTx. More PFS notes. Two FDA De Novos.

11.07.25

6 min. Read

Pricing for Sword Health, Hinge Health, Joint Academy in the UK.

10.31.25

7 min. Read

Spring, Slingshot AI, Click and others write FDA about GenAI. Big Health board departs.

10.24.25

7 min. Read